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Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation:
Comparison of the ABC-Stroke and CHA2DS2-VASc Scores
Jose Miguel Rivera-Caravaca, RN, MSc; Vanessa Roldan, MD, PhD; Marıa Asuncion Esteve-Pastor, MD; Mariano Valdes, MD, PhD;
Vicente Vicente, MD, PhD; Gregory Y. H. Lip, MD;* Francisco Marın, MD, PhD*
Background-—The ABC-stroke score (age, biomarkers [N-terminal fragment B-type natriuretic peptide, high-sensitivity troponin],
and clinical history [prior stroke/transient ischemic attack]) was proposed to predict stroke in atrial fibrillation (AF). This score was
derived/validated in 2 clinical trial cohorts in which patients with AF were highly selected and carefully followed-up. However, the
median follow-up was 1.9 years in the trial cohort; therefore, its long-term predictive performance remains uncertain. This study
aimed to compare the long-term predictive performances of the ABC-stroke and CHA2DS2-VASc (cardiac failure or dysfunction,
hypertension, age ≥75 [doubled], diabetes mellitus, stroke [doubled]—vascular disease, age 65 to 74 years and sex category
[female]) scores in a cohort of anticoagulated patients with AF.
Methods and Results-—We recruited 1125 consecutive patients with AF who were stable on vitamin K antagonists and followed-up
for a median of 6.5 years. ABC-stroke and CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age ≥75 [doubled],
diabetes mellitus, stroke [doubled]—vascular disease, age 65 to 74 years and sex category [female]) scores were calculated and
compared. Median CHA2DS2-VASc and ABC-stroke scores were 4 (interquartile range 3–5) and 9.1 (interquartile range 7.3–11.3),
respectively. There were 114 ischemic strokes (1.55% per year) at 6.5 years. The C-index of ABC-stroke at 3.5 years was
significantly higher than CHA2DS2-VASc (0.663 versus 0.600, P=0.046), but both C-indexes were nonsignificantly different at
6.5 years. Integrated discrimination improvement showed a small improvement (<2%) in sensitivity at 3.5 and 6.5 years with ABC-
stroke. For ABC-stroke, net reclassification improvement was nonsignificantly different at 3.5 years, and showed a negative
reclassification at 6.5 years compared with CHA2DS2-VASc. Decision curve analyses did not show a marked improvement in
clinical usefulness of the ABC-stroke score over the CHA2DS2-VASc score.
Conclusions-—In anticoagulated patients with AF followed-up over a long-term period, the novel ABC-stroke score does not offer
significantly better predictive performance compared with the CHA2DS2-VASc score. ( J Am Heart Assoc. 2017;6:e006490. DOI:
10.1161/JAHA.117.006490.)
Key Words: anticoagulants • atrial fibrillation • biomarkers • risk prediction • stroke
S troke risk is increased in patients with atrial fibrillation,but this risk is not homogeneous and depends on the
presence of various risk factors. The more common stroke
risk factors have been used to formulate risk scores, such as
the CHA2DS2-VASc score, to help select patients who need
oral anticoagulant therapy.1 The CHA2DS2-VASc score has
been widely validated and its use for stroke risk prediction is
recommended by current guidelines for the management of
AF.2–4
For many years, the role of biomarkers in predicting
adverse events and improving risk stratification in cardiovas-
cular disease has been investigated.5 Biomarkers have been
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proposed to help refine stroke risk stratification in AF for over
a decade,6 and recent guidelines have proposed consideration
of biomarkers to aid risk stratification.2 More recently, the
ABC-stroke score (age, cardiac biomarkers [NT-proBNP
(N-terminal fragment B-type natriuretic peptide)], high-sensi-
tivity cardiac troponin), and clinical history [prior stroke/
transient ischemic attack]) has been proposed to predict
stroke in patients with AF.7 The ABC-stroke score was derived
and validated in 2 clinical trial cohorts in which patients with
AF are often highly selected and carefully followed-up. “Real-
world” patients tend to be older, with associated comorbidi-
ties and polypharmacy. The median follow-up was 1.9 years in
the trial cohort, therefore the long-term predictive perfor-
mance of ABC-stroke is uncertain.
In the present study, we compared the long-term predictive
performance of the ABC-stroke score with CHA2DS2-VASc in a
real-world cohort of anticoagulated patients with AF.
Methods
We recruited consecutive patients with paroxysmal, persis-
tent, or permanent nonvalvular AF who were stable on vitamin
K antagonist (international normalized ratio [INR] 2.0–3.0) for
at least the previous 6 months in our single anticoagulation
center in a tertiary hospital in Murcia (Southeast Spain), from
May 1, 2007, to December 1, 2007. At entry, all patients were
receiving anticoagulation therapy with acenocoumarol (the
most common vitamin K agonist used in Spain) and consis-
tently achieved an INR between 2.0 and 3.0 during the
previous 6 months (to ensure baseline homogeneity avoiding
any influence of fluctuant INR in the value of biomarkers). We
excluded patients with rheumatic mitral valves or prosthetic
heart valves and those with any acute coronary syndrome,
stroke, hemodynamic instability, hospital admissions or
surgical interventions in the preceding 6 months.
At baseline, a complete medical history was recorded and
stroke risk (CHA2DS2-VASc) and bleeding risk (HAS-BLED
[hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile INR, elderly (>65 years),
drugs/alcohol concomitantly]) were calculated. The time in
therapeutic range was calculated at 6 months after entry by
the linear interpolation method of Rosendaal. The ABC-stroke
score was calculated using an Excel-based calculator that
performed the results according to the nomogram proposed
by Hijazi et al.7 This calculator provided the total score and
the corresponding predicted 1- and 3-year risk of stroke. In
the present study, we used the “Troponin T” version of the
nomogram, provided by Hijazi et al in their supplementary
material online.7
Blood Samples and Laboratory Analysis
At entry, blood samples were drawn atraumatically and
without stasis into syringes preloaded with trisodium citrate
(0.011 mol/L). Platelet-poor plasma fractions were obtained
by centrifugation at 4°C for 20 minutes at 2200g. Aliquots
were stored at 80°C to allow batch analysis. High-sensitivity
troponin T and NT-proBNP levels were assessed at the time of
patient inclusion by electrochemiluminescence in an auto-
mated analyzer (Cobas e 601, Roche Diagnostica). The intra-
assay variation coefficient was 5.6% and the lower limits of
detection of these assays were 3.0 pg/mL for high-sensitivity
troponin T and 5.0 pg/mL for NT-proBNP.
Study Outcomes
To investigate clinical outcomes at 3 and 6 years, we
analyzed stroke events at a median of 3.5 years (interquartile
range [IQR] 3.1–3.6) of follow-up, and a final analysis at a
median of 6.5 years (IQR 4.3–7.9). Follow-up was performed
by personal interview at each visit to the anticoagulation clinic
and through medical records, and no patient was lost to
follow-up. The primary end point for the present analysis was
ischemic stroke and was defined as the sudden onset of a
focal neurological deficit in a location consistent with the
territory of a major cerebral artery resulted of an obstruction
documented by imaging, surgery, or autopsy. Other adverse
events were recorded, such as major bleeding (based on 2005
Clinical Perspective
What Is New?
• Recent guidelines suggest the use of biomarkers for risk
stratification in atrial fibrillation.
• In this first study comparing the ABC-stroke (age, biomark-
ers [N-terminal fragment B-type natriuretic peptide, high-
sensitivity troponin], and clinical history [prior stroke/tran-
sient ischemic attack]) and CHA2DS2-VASc scores in a “real-
world” cohort of patients with atrial fibrillation, the
biomarker-based ABC-stroke score loses much of its
prognostic value in the long term (by 6.5 years).
• Hence, there is little difference in the clinical utility of the
ABC-stroke score compared with the clinical risk factor–
based CHA2DS2-VASc score.
What Are the Clinical Implications?
• Although measuring biomarkers may help improve predic-
tion of patients at high risk (at least statistically), this is at
the cost of adding substantial complexity, expense, and lack
of practicality.
• CHA2DS2-VASc score has the advantage of simplicity and
performed better than the ABC-stroke score in categorizing
patients at low risk, thus allowing clinicians to rapidly
estimate whether oral anticoagulation is indicated.
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International Society on Thrombosis and Haemostasis crite-
ria8) and all-cause deaths. The investigators identified,
confirmed, and recorded all adverse events, as well as other
clinical outcomes.
The study protocol was approved by the ethics committee
from University Hospital Morales Meseguer and was per-
formed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki and its later amendments. All
patients gave informed consent to participate in the study.
Statistical Analysis
Categorical variables were expressed as frequencies and
percentages. Continuous variables were tested for normality
by the Kolmogorov–Smirnov test and presented as meanSD
or median and IQR, as appropriate.
The Pearson chi-square test was used to compare
proportions. Cox proportional hazard regression models were
performed to determine the association between higher
values of the ABC-stroke and CHA2DS2-VASc scores and
ischemic stroke. Differences in event-free survival between
patients with different risk categories of ABC-stroke and
CHA2DS2-VASc were reflected by Kaplan–Meier curves.
Correlation between ABC-stroke and CHA2DS2-VASc scores
were performed using the Spearman’s Rho.
Receiver operating characteristic curves were applied to
evaluate the predictive ability (expressed as C-indexes) of the
CHA2DS2-VASc and ABC-stroke scores. Comparisons of
receiver operating characteristic curves were performed by
the DeLong et al method.9 Discrimination and reclassification
performance of the 2 scores were evaluated by calculating the
integrated discrimination improvement and the net reclassi-
fication improvement, as described by Pencina et al.10 We
also estimated the clinical usefulness and net benefit of the
ABC-stroke score in comparison to CHA2DS2-VASc using the
decision curve analysis, according to the method proposed by
Vickers et al.11,12
A P<0.05 was accepted as statistically significant. Statis-
tical analyses were performed using SPSS version 19.0 (SPSS
Inc), MedCalc version 16.4.3 (MedCalc Software bvba), and
STATA version 12.0 (Stata Corp, College Station, TX) for
Windows.
Results
We included 1125 patients (49.7% men) with a median age of
76 years (IQR 71–81). A summary of baseline clinical
characteristics is shown in Table 1. Median CHA2DS2-VASc
and ABC-stroke scores were 4 (IQR 3–5) and 9.1 (IQR 7.3–
11.3), respectively. The median time in the therapeutic range
at 6 months after entry was 80% (IQR 66–100) and the
median HAS-BLED score was 2 (IQR 2–3). During 6.5 years
(IQR 4.3–7.9) of follow-up, there were 203 major bleeding
events (18%, 2.77% per year) and 450 patients died (40%,
6.15% per year).
At the interim 3.5 years (IQR 3.1–3.6) of follow-up, 58
patients experienced an ischemic stroke (5.2%, an annual rate
of 1.50% per year). Of these, 98.3% were “high risk” by
CHA2DS2-VASc category (ie, score ≥2) and 70.7% were high
risk by ABC-stroke category (ie, predicted event rate >2%). At
the end of follow-up, ie, at 6.5 years (IQR 4.3–7.9), 114
patients experienced an ischemic stroke (10.1%, annual rate
of 1.55% per year). Of these, 99.1% were high risk by
CHA2DS2-VASc category and 68.4% by ABC-stroke (Table 2).
Based on Cox regression analyses, the overall risk at
3.5 years for each score point was 1.28 (95% CI, 1.10–1.60;
P=0.003) for CHA2DS2-VASc and 1.22 (95% CI, 1.13–1.31;
P<0.001) for ABC-stroke. At 6.5 years, corresponding figures
were 1.40 (95% CI, 1.25–1.57; P<0.001) for CHA2DS2-VASc
and 1.24 (95% CI, 1.17–1.30; P<0.001) for ABC-stroke
(Table S1).
Survival analyses by the Kaplan–Meier curves within
different risk categories of ABC-stroke and CHA2DS2-VASc
are shown in Figure 1. The Kaplan–Meier curves show that
the “low-risk” category as defined by CHA2DS2-VASc were
clearly low risk, with virtually no events at 3.5 and 6.5 years.
In contrast, the low-risk group defined by ABC-stroke
experienced 17 and 36 ischemic stroke events at 3.5 and
6.5 years, respectively (annual rates of 0.43% per year and
0.50% per year). Kaplan–Meir analysis of the low-moderate
risk category defined by CHA2DS2-VASc and ABC-stroke
scores also show a significant difference at 6.5 years
(CHA2DS2-VASc: log-rank test 7.31, P=0.007; ABC-stroke:
log-rank test 27.08, P<0.001) (Figure S1).
Prediction of Patients at High Risk Who Sustain
Strokes
With regard to predictive performance, the C-index of the
ABC-stroke at 3.5 years was higher from that of CHA2DS2-
VASc which was statistically significant (0.663 versus 0.600,
P=0.046) (Table 3). At 6.5 years, the C-index of the ABC-
stroke was 0.662, while the C-index of CHA2DS2-VASc was
0.620, and nonsignificantly different (Table 3, Figure S2).
Based on the integrated discrimination improvement, the
ABC-stroke score had a poor improvement (<2%) in sensitivity
at 3.5 and 6.5 years. Net reclassification improvement
analyses demonstrated a nonsignificant improvement in
reclassification at 3.5 years and a (significant) negative
reclassification at 6.5 years with the ABC-stroke score
compared with CHA2DS2-VASc (Table 3).
When we plotted decision curve analyses to assess the
clinical usefulness in real practice, use of the ABC-stroke
score showed an approximate net benefit of 0.5% at 3.5 years
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and 1% at 6.5 years, over the CHA2DS2-VASc score (Fig-
ure 2).
Prediction of Low Risk Patients
The proportion of patients categorized as low-medium risk by
the CHA2DS2-VASc and ABC-stroke scores were 5.6% and
48.2%, respectively. Importantly, a high proportion (89.3%) of
patients classified as low-medium risk according to the ABC-
stroke score could be categorized as high risk (score ≥2) with
the CHA2DS2-VASc score (Figure S3). As expected, the ABC-
stroke score and CHA2DS2-VASc score showed a moderate
correlation (Spearman’s rho: 0.539; 95% CI, 0.496–0.580
[P<0.001]).
Only 1 of the patients categorized as having low-moderate
risk by CHA2DS2-VASc score experienced an ischemic stroke
Figure 1. Event-free survival for ischemic stroke according to the risk categories of each score. Blue
line=low risk; green line=medium risk; red line=high risk. CHA2DS2-VASc (cardiac failure or dysfunction,
hypertension, age ≥75 [doubled], diabetes mellitus, stroke [doubled]—vascular disease, age 65 to 74 years
and sex category [female]) categories were defined as low risk (score=0), medium risk (score=1), and high
risk (score ≥2). ABC-stroke (age, biomarkers [N-terminal fragment B-type natriuretic peptide, high-
sensitivity troponin], and clinical history [prior stroke/transient ischemic attack]) categories were defined
as low risk (<1% predicted 1-year risk of stroke), medium risk (1–2% predicted 1-year risk of stroke), and
high risk (>2% predicted 1-year risk of stroke). IQR indicates interquartile range.
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at 6.5 years (0.31% per year); however, with the ABC-stroke
score, patients in the low-moderate risk category had 36
strokes at 6.5 years (1.1% per year). This means that at
6.5 years, 6.64% of patients categorized as having low-
medium risk with the ABC-stroke score experienced an
ischemic stroke, while only 1.59% of patients categorized as
having low-medium risk with the CHA2DS2-VASc score
experienced an ischemic stroke. Patients at low-medium risk
in the ABC-stroke group still had a median CHA2DS2-VASc
score of 3 (IQR 2–4) and a high risk of stroke per every
CHA2DS2-VASc score point (hazard ratio, 1.3; 95% CI, 1.09–
1.70; P=0.007).
Discussion
In this analysis of anticoagulated patients with AF, our
principal finding was that the ABC-stroke score did not
provide better predictive accuracy for stroke in patients with
AF followed-up over a long-term period, in comparison to the
CHA2DS2-VASc score. Second, the CHA2DS2-VASc score
performed well in identifying patients at “low risk,” better
than ABC-stroke.
The role of biomarkers in the prediction of adverse
outcomes in patients with AF has been extensively investi-
gated. These include some biomarkers related to hemostasis
(fibrin D-dimer, plasminogen activator inhibitor, tissue factor,
and P-selectin), inflammation (C-reactive protein, interleukin
6, galectin-3, tumor necrosis factor-a), myocardial stress or
injury (cardiac troponins and natriuretic peptides), endothe-
lial damage or dysfunction (thrombomodulin, E-selectin, and
von Willebrand factor), fibrosis and extracellular matrix
turnover (transforming growth factor-b, myeloperoxidase,
and metallopeptidases and their inhibitors), renal function
(Cystatin C), or genetic factors (micro-RNA and single-
nucleotide polymorphisms).13,14 Indeed, inflammatory and
hemostatic markers such us plasminogen activator inhibitor-
1, thrombin-antithrombin, and D-dimer have all been shown
to be associated with stroke and thromboembolic events.15
Table 2. Distribution of Ischemic Strokes According to the Stroke Risk Scores Categories
Risk Categories
CHA2DS2-VASc Score ABC-Stroke Score
No. (%) Annual Rate (% per y) No. (%) Annual Rate (% per y)
At 3.5 y Ischemic strokes (n=58)
Low risk 0 (0.0) 0 1 (1.7) 0.54
Medium risk 1 (1.7) 0.58 16 (27.6) 0.96
High risk 57 (98.3) 1.55 41 (70.7) 2.03
At 6.5 y Ischemic strokes (n=114)
Low risk 0 (0.0) 0 1 (0.9) 0.30
Medium risk 1 (0.9) 0.31 35 (30.7) 1.10
High risk 113 (99.1) 1.64 78 (68.4) 2.06
ABC-stroke indicates age, biomarkers (N-terminal fragment B-type natriuretic peptide, high-sensitivity troponin), and clinical history (prior stroke/transient ischemic attack); CHA2DS2-
VASc, cardiac failure or dysfunction, hypertension, age ≥75 (doubled), diabetes mellitus, stroke (doubled)—vascular disease, age 65 to 74 years and sex category (female).
Table 3. C-Indexes of the ROC Curves, ROC Curves Comparison, IDI, and NRI of the ABC-Stroke Score in Comparison With
CHA2DS2-VASc Score at 3.5 and 6.5 Years
C-Index 95% CI P Value z Statistic* P Value* IDI P Value NRI P Value
At 3.5 y
ABC-stroke score 0.663 0.634 to 0.690 <0.001 1.998 0.046 0.019 0.002 0.002 0.903
CHA2DS2-VASc score 0.600 0.567 to 0.625 <0.001
At 6.5 y
ABC-stroke score 0.662 0.633 to 0.690 <0.001 1.574 0.116 0.019 0.002 0.053 <0.001
CHA2DS2-VASc score 0.620 0.590 to 0.648 <0.001
ABC-stroke indicates age, biomarkers (N-terminal fragment B-type natriuretic peptide, high-sensitivity troponin), and clinical history (prior stroke/transient ischemic attack); CHA2DS2-
VASc, cardiac failure or dysfunction, hypertension, age ≥75 (doubled), diabetes mellitus, stroke (doubled)—vascular disease, age 65 to 74 years and sex category (female); IDI, integrated
discriminatory improvement; NRI, net reclassification index; ROC, receiver operating characteristic.
*For C-index comparison.
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Similarly, interleukin 6 has been demonstrated to be related
to mortality, thromboembolic events, and major bleeding in
patients with AF, while C-reactive protein was associated
with myocardial infarction.16 In the ARISTOTLE biomarker
substudy (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation), a high level of
growth differentiation factor 15, a member of the trans-
forming growth factor-b cytokine family, was an independent
risk factor for major bleeding, mortality, and stroke in
patients with AF.13,17,18
One of the most well-studied biomarkers in AF is the von
Willebrand factor, which is a marker of endothelial damage/
dysfunction.5 In 2006, the von Willebrand factor was first
reported to refine clinical stroke risk stratification using the
CHADS2 and Birmingham (the precursor of CHA2DS2-VASc)
scores.6 More recently, we confirmed the prognostic value of
the von Willebrand factor in a contemporary cohort of patients
with AF and how its addition to the CHA2DS2-VASc and HAS-
BLED scores improved the prediction of cardiovascular events
(including cardiovascular mortality), stroke, and major bleed-
ing; however, the clinical utility of adding this biomarker to
clinical scores remains limited given the marginal net benefit,
especially after a long-term follow-up.19
Renewed interest into biomarkers is consequent upon
publication of substudies from the large randomized trials of
anticoagulation in AF. For example, Hijazi et al20–22 deter-
mined that high-sensitivity cardiac troponins I and T, as well
as NT-proBNP, provided important prognostic information in
patients with AF. In a subanalysis of the ENGAGE AF-TIMI 48
trial (Effective Anticoagulation With Factor Xa Next Generation
in Atrial Fibrillation–Thrombolysis in Myocardial Infarction
Study 48), adding troponin I, NT-proBNP, and D-dimer levels
to the CHA2DS2-VASc score incrementally enhanced risk
assessment for stroke, systemic embolism, and death com-
pared with traditional clinical risk stratification.23 In smaller
real-world series, Providência et al24 demonstrated that the
addition of troponin to clinical risk scores helped identify
patients at greater risk of intracardiac thrombi, while Roldan
et al25 demonstrated that increased blood concentrations of
NT-proBNP identified patients with AF at risk for stroke and
provided complementary prognostic information to the
CHA2DS2-VASc score. Another biomarker, B-type natriuretic
peptide, has been shown to be a predictor of incident AF and
improved risk stratification in the Framingham cohort.26 In
contrast, Potpara et al27 showed that adding troponin I,
fibrinogen, and C-reactive protein to the CHA2DS2-VASc score
did not significantly increase the predictive ability of the risk
model.
Despite the increasing number of studies investigating
biomarkers in AF, their value in the everyday real-world
clinical evaluation of patients with AF is debated. For example,
the ABC-stroke score was developed using data from patients
with AF who had biomarkers measured at entry into the
ARISTOTLE trial. This risk score demonstrated improved
predictive performance (at least statistically) compared with
CHA2DS2-VASc, but the follow-up was only to 3 years in the
external validation cohort.7 In clinical trials, patients are often
carefully selected with specific inclusion/exclusion criteria
and followed-up in a protocol-based manner, whereas patients
with AF in real-world clinical practice tend to be older,
with many associated comorbidities and polypharmacy, and
have variable treatment adherence and follow-up.28 In
addition, many biomarkers are concurrently predictive of
ischemic stroke, bleeding, myocardial infarction, venous
Figure 2. Decision curves for the ABC-stroke (age, biomarkers
[N-terminal fragment B-type natriuretic peptide, high-sensitivity
troponin], and clinical history [prior stroke/transient ischemic
attack]) and CHA2DS2-VASc (cardiac failure or dysfunction,
hypertension, age ≥75 [doubled], diabetes mellitus, stroke
[doubled]—vascular disease, age 65 to 74 years and sex
category [female]) scores. This analysis shows the clinical
usefulness of each score based on a continuum of potential
thresholds for ischemic stroke (x axis) and the net benefit of using
the model to stratify patients at risk (y axis) relative to assuming
that no patient will have an ischemic stroke. IQR indicates
interquartile range.
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thromboembolism, heart failure, and death, which may lead to
uncertainty among clinicians over which end point should be
the priority. Biomarkers are also subject to laboratory assay
variability and some have a diurnal variation in levels. All of
these factors may make accurate estimation of stroke and
bleeding risk more difficult and less practical with a
biomarker-based strategy.
Recently, the validation of risk scores in other populations
who the score was not created for has been criticized, as
validation studies are only valid for the data source in which
they are performed29; however, surprisingly, the recent
European Society of Cardiology guidelines suggest the use
of biomarkers based on the ABC scores.7,30 Hence, it would
be highly relevant to see how this score performed in real-
world patients in everyday clinical practice. Our study shows
that in the long term (particularly from 3.5 years of follow-up)
the biomarker-based ABC-stroke score loses much of its
prognostic value and the clinical usefulness does not differ
much from a simple clinical risk score, CHA2DS2-VASc.
Indeed, improvement of the net benefit was marginal (≤1%)
and measurement of (multiple) biomarkers may help improve
the prediction of patients at high risk; however, this would be
at the cost of adding substantial complexity, expense, and
lack of practicality.14
One of the advantages of the CHA2DS2-VASc score is its
relative simplicity, which allows clinicians to rapidly estimate
the risk of stroke in patients with AF and whether oral
anticoagulant therapy is indicated. Indeed, the default should
be to offer stroke prevention (ie, oral anticoagulants) unless
the patient is initially shown to be at low risk and CHA2DS2-
VASc performs well in categorizing those at low risk (stroke
<1% per year).
Limitations
This study is limited by its recruitment of a white-based
patient population and by its single-center design. At the
beginning of the study, all patients were stable with a vitamin
K agonist (INR 2.0–3.0) during the previous 6 months to
ensure homogeneity, thus future studies are needed to
validate our results in a population taking other oral
anticoagulation therapies. The strict selection criteria (all
INRs between 2 and 3 at 6 months before entry) may not
reflect “typical” clinical practice, but the long follow-up and
standard care received make this cohort suitable. Although
our data set was collected prospectively, biomarker determi-
nations and all statistical analyses were performed retrospec-
tively. Indeed, patients with recent acute coronary syndrome,
stroke, unstable chest pain, or any hemodynamic instability,
as well as patients with hospital admission or surgical
intervention in the past 6 months were excluded, since
biomarkers would be expected to be abnormally elevated in
these patients. We consider that a 6-month period would be
enough to stabilize biomarkers values and—most importantly
—ensured homogeneity at baseline, avoiding the bias
produced by high biomarkers at entry. We also measured
biomarkers at baseline, but we acknowledge that levels may
fluctuate over time and during the acute phase of adverse
events. Indeed, most of the studies on biomarkers and AF are
based on a single unique blood sample determination at
baseline. Of note, participants were carefully followed-up and
all events (even early ones) were recorded.
Conclusions
In anticoagulated patients with AF, the novel ABC-stroke
score does not offer significantly better predictive perfor-
mance compared with the CHA2DS2-VASc score over a long-
term period of follow-up (median 6.5 years). Importantly, the
CHA2DS2-VASc score performed well in identifying patients at
low risk better than the ABC-stroke score.
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Table S1. Univariate Cox regression analysis between stroke risk scores and ischaemic 
stroke. 
 HR* 95% CI p 
At 3.5 years 
CHA2DS2-VASc score 1.28 1.10-1.50 0.003 
ABC-stroke score 1.22 1.13-1.31 <0.001 
At 6.5 years 
CHA2DS2-VASc score 1.40 1.25-1.57 <0.001 
ABC-stroke score 1.24 1.17-1.30 <0.001 
CI = confidence interval; HR = hazard ratio. *as per every score point. 
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Figure S1. Kaplan-Meier analysis for ischaemic stroke according to the low risk categories 
of each score. 
 
 
Solid line = Low-medium risk; Dash line = High risk. 
CHA2DS2-VASc categories were defined as low-medium risk (score = 0 or 1), and high risk 
(score = ≥2). ABC-stroke categories were defined as low-medium risk (<1% or 1-2% 
predicted 1-year risk of stroke) and high risk (>2% predicted 1-year risk of stroke). 
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Figure S2. Comparison of the ROC curves of the ABC-stroke and CHA2DS2-VASc scores. 
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Figure S3. Correlation of the ABC-stroke and CHA2DS2-VASc scores. Focus on low-
moderate risk patients with the ABC-stroke score.  
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